GlassScriptPhysician profile
Noah N Settergren
NPI 1285072587
$7,718.68
in general payments reported to CMS, 2019-2025
34 companies · $1,969 in 2025
The $1,969 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $140 · 2021: $174 · 2022: $674 · 2023: $1,464 · 2024: $2,532 · 2025: $1,969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,866 · Education: $98.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,866.00 |
| Education | $98.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,773.54 | 2019-2025 | Rinvoq, Linzess, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $1,007.99 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $827.56 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Gilead Sciences, INC. | $605.62 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $571.86 | 2023-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $483.30 | 2019-2025 | Xifaxan |
| Pfizer INC. | $261.99 | 2019-2025 | |
| Genzyme Corporation | $244.17 | 2022-2025 | |
| Ardelyx, INC. | $215.48 | 2023-2025 | Ibsrela |
| Celgene Corporation | $180.27 | 2021-2024 | Zeposia |
| Organon LLC | $177.50 | 2022-2024 | Renflexis, Hadlima |
| Phathom Pharmaceuticals, INC. | $139.19 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $129.54 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $127.09 | 2024-2025 | Resmetirom, Rezdiffra |
| Merck Sharp & Dohme LLC | $121.79 | 2019-2024 | Zerbaxa, Dificid |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocompatibles, INC. | $115.40 | 2019 | |
| Erbe USA INC | $90.53 | 2019 | |
| Intercept Pharmaceuticals, INC. | $90.45 | 2019-2024 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $77.18 | 2021-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $60.93 | 2023-2024 | Rebyota |
| Celltrion USA INC. | $56.26 | 2025 | Vegzelma |
| Ethicon US, LLC | $49.24 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $41.24 | 2021-2022 | |
| Echosens North America, INC. | $36.08 | 2024 | Fibroscan |
| Braintree Laboratories, INC. | $33.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.91 | 2023 | Cyltezo |
| Redhill Biopharma INC. | $31.21 | 2022 | |
| Aimmune Therapeutics, INC. | $30.39 | 2024-2025 | Zenpep |
| Astrazeneca Pharmaceuticals LP | $23.81 | 2024 | Wainua |
| Novo Nordisk INC | $21.29 | 2025 | Wegovy |
| Enterra Medical, INC. | $19.63 | 2025 | |
| Exact Sciences Corporation | $17.59 | 2025 | Cologuard Collection Kit |
| Medtronic, INC. | $14.06 | 2025 | Pillcam |
| Micro-Tech Endoscopy USA, INC. | $10.11 | 2023 | Ligator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noah Settergren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.